MLYS — Mineralys Publishes Phase 2 Explore‑CKD Data for Lorundrostat in Kidney International

The news & why it matters

Mineralys announced publication of Phase 2 Explore‑CKD trial results for its drug lorundrostat in Kidney International (press release posted Oct. 28, 2026). The supplied item records the study as showing significant efficacy and safety findings. A published Phase 2 efficacy/safety readout is a material, company‑level clinical milestone that can trigger increased investor attention, intraday share and options activity, and next‑step development or regulatory discussion.

Sources: S1

What traders should watch

Read the Kidney International paper and the company IR posting (link in the digest) for full endpoints, patient counts, statistical details and the safety breakdown — the supplied market data do not include numeric results. After the publication, monitor MLYS price, volume and options flow for confirmation of market interest and look for any company follow‑ups (presentations, conference abstracts or SEC filings) that disclose detailed data or next steps.

Sources: S1

What remains uncertain

• SMC news digest links to the company press release and records the Kidney International publication, but the supplied market data do not include the study’s numeric endpoints, patient counts, p‑values or detailed safety tables — consult the original Kidney International article and the issuer release for the full data.